|
US7888121B2
(en)
*
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
US11311574B2
(en)
|
2003-08-08 |
2022-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for targeted cleavage and recombination
|
|
ES2646138T3
(es)
|
2009-10-22 |
2017-12-12 |
Sangamo Biosciences, Inc. |
Proteínas de dedos de cinc manipuladas genéticamente dirigidas a los genes de planta involucrados en la biosíntesis de ácidos grasos
|
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
|
US12492376B2
(en)
|
2009-10-29 |
2025-12-09 |
The Trustees Of Dartmouth College |
T-cell receptor-deficient T cell compositions
|
|
CA3205636A1
(en)
|
2011-04-20 |
2012-10-26 |
University Of Washington Through Its Center For Commercialization |
Beta-2 microglobulin-deficient cells
|
|
EP2737063B1
(en)
*
|
2011-07-25 |
2016-06-01 |
Sangamo BioSciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
US10704021B2
(en)
|
2012-03-15 |
2020-07-07 |
Flodesign Sonics, Inc. |
Acoustic perfusion devices
|
|
US9637739B2
(en)
*
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
EP4253409A3
(en)
*
|
2012-04-17 |
2023-12-06 |
University of Washington through its Center for Commercialization |
Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof
|
|
US9834786B2
(en)
*
|
2012-04-25 |
2017-12-05 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
|
US9790278B2
(en)
|
2012-05-07 |
2017-10-17 |
The Trustees Of Dartmouth College |
Anti-B7-H6 antibody, fusion proteins, and methods of using the same
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
JP6401704B2
(ja)
|
2012-10-10 |
2018-10-10 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｔ細胞を修飾する化合物およびその使用
|
|
US20140115728A1
(en)
|
2012-10-24 |
2014-04-24 |
A. Joseph Tector |
Double knockout (gt/cmah-ko) pigs, organs and tissues
|
|
EP2931891B1
(en)
*
|
2012-12-17 |
2019-05-15 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
|
EP2970886B1
(en)
*
|
2013-03-12 |
2018-05-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of hla
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
EP2975942B1
(en)
*
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
EP3789487A1
(en)
*
|
2013-04-03 |
2021-03-10 |
Memorial Sloan Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
LT2986729T
(lt)
|
2013-04-16 |
2018-10-25 |
Regeneron Pharmaceuticals, Inc. |
Žiurkės genomo tikslinė modifikacija
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
CN112795594B
(zh)
|
2013-05-14 |
2025-09-19 |
得克萨斯州大学系统董事会 |
工程化嵌合抗原受体(car)t细胞的人应用
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US10117899B2
(en)
|
2013-10-17 |
2018-11-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
CN110951779B
(zh)
|
2013-12-11 |
2024-04-16 |
瑞泽恩制药公司 |
用于靶向修饰基因组的方法和组合物
|
|
CA3225456A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
WO2015105955A1
(en)
|
2014-01-08 |
2015-07-16 |
Flodesign Sonics, Inc. |
Acoustophoresis device with dual acoustophoretic chamber
|
|
EP3505623B1
(en)
|
2014-02-14 |
2025-12-24 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
JP6640726B2
(ja)
|
2014-02-14 |
2020-02-05 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
キメラ抗原受容体及びその製造方法
|
|
KR102228828B1
(ko)
|
2014-03-11 |
2021-03-16 |
셀렉티스 |
동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
|
|
CN106163547A
(zh)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
PT3119807T
(pt)
*
|
2014-03-19 |
2019-09-04 |
Cellectis |
Recetores de antigénios quiméricos específicos de cd123 para imunoterapêutica do cancro
|
|
CN111514283B
(zh)
|
2014-04-07 |
2025-10-14 |
诺华股份有限公司 |
使用抗cd19嵌合抗原受体治疗癌症
|
|
EP3129473B8
(en)
|
2014-04-11 |
2020-12-23 |
Cellectis |
Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment
|
|
AU2015248956B2
(en)
*
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
|
US20170044500A1
(en)
*
|
2014-04-24 |
2017-02-16 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
SG11201609634YA
(en)
|
2014-06-06 |
2016-12-29 |
Regeneron Pharma |
Methods and compositions for modifying a targeted locus
|
|
PL3161128T3
(pl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Sposoby i kompozycje do celowanych modyfikacji genetycznych i sposoby zastosowania
|
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
EP3172234B1
(en)
|
2014-07-21 |
2020-04-08 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
|
WO2016014837A1
(en)
|
2014-07-25 |
2016-01-28 |
Sangamo Biosciences, Inc. |
Gene editing for hiv gene therapy
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
AU2015305531B2
(en)
|
2014-08-19 |
2021-05-20 |
Novartis Ag |
Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
|
|
US10435677B2
(en)
|
2014-09-16 |
2019-10-08 |
Sangamo Therapeutics, Inc. |
Genetically modified human cell with a corrected mutant sickle cell mutation
|
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
|
DK3220926T3
(da)
|
2014-11-17 |
2025-03-24 |
Adicet Therapeutics Inc |
Konstruerede gamma-delta-t-celler
|
|
CA3176380A1
(en)
|
2014-11-21 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
EP3653048B9
(en)
|
2014-12-19 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
WO2016112779A1
(en)
*
|
2015-01-17 |
2016-07-21 |
Zhejiang University |
Modified cells evoking reduced immunogenic responses
|
|
HK1246690A1
(zh)
|
2015-01-21 |
2018-09-14 |
Sangamo Therapeutics, Inc. |
用於鉴定高度特异性核酸酶的方法和组合物
|
|
JP6800859B2
(ja)
|
2015-01-26 |
2020-12-16 |
フェイト セラピューティクス，インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US11708572B2
(en)
|
2015-04-29 |
2023-07-25 |
Flodesign Sonics, Inc. |
Acoustic cell separation techniques and processes
|
|
US11377651B2
(en)
|
2016-10-19 |
2022-07-05 |
Flodesign Sonics, Inc. |
Cell therapy processes utilizing acoustophoresis
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
US10808020B2
(en)
*
|
2015-05-12 |
2020-10-20 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
US20180184630A1
(en)
*
|
2015-06-26 |
2018-07-05 |
Indiana University Research & Technology Corporation |
Transgenic pigs with genetic modifications of sla
|
|
WO2017011519A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
KR20180041152A
(ko)
|
2015-08-11 |
2018-04-23 |
셀렉티스 |
Cd38 항원 타겟팅 및 cd38 유전자 불활성화를 위하여 조작된 면역치료용 세포들
|
|
CN108348576B
(zh)
|
2015-09-23 |
2022-01-11 |
桑格摩生物治疗股份有限公司 |
Htt阻抑物及其用途
|
|
CN108601821B
(zh)
|
2015-10-05 |
2023-09-19 |
精密生物科学公司 |
包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
|
|
ES2883116T3
(es)
*
|
2015-10-05 |
2021-12-07 |
Prec Biosciences Inc |
Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
|
|
CN116712535A
(zh)
|
2015-10-16 |
2023-09-08 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
|
KR20250022906A
(ko)
|
2015-10-28 |
2025-02-17 |
상가모 테라퓨틱스, 인코포레이티드 |
간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
|
|
JP7534070B2
(ja)
|
2015-11-04 |
2024-08-14 |
フェイト セラピューティクス，インコーポレイテッド |
造血細胞分化を誘導するための方法および組成物
|
|
CN115806940A
(zh)
|
2015-11-04 |
2023-03-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
|
CA3004349A1
(en)
|
2015-11-23 |
2017-06-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
NZ782858A
(en)
|
2015-12-04 |
2025-08-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
JP7128741B2
(ja)
|
2015-12-18 |
2022-08-31 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｔ細胞受容体の標的化破壊
|
|
WO2017106537A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the mhc cell receptor
|
|
EP4219689A3
(en)
|
2015-12-30 |
2023-12-20 |
Novartis AG |
Immune effector cell therapies with enhanced efficacy
|
|
WO2017123757A1
(en)
|
2016-01-15 |
2017-07-20 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
KR20180134385A
(ko)
|
2016-04-15 |
2018-12-18 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
|
AU2017250769B2
(en)
|
2016-04-15 |
2022-07-14 |
Memorial Sloan Kettering Cancer Center |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
EP3454870A4
(en)
|
2016-05-12 |
2020-03-04 |
Adicet Bio Inc. |
METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
|
|
CN109475109B
(zh)
|
2016-05-20 |
2021-10-29 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
MX2019002207A
(es)
|
2016-08-24 |
2019-07-15 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas.
|
|
ES2901989T3
(es)
|
2016-08-24 |
2022-03-24 |
Sangamo Therapeutics Inc |
Nucleasas específicas de objetivo modificadas
|
|
AU2017324462B2
(en)
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
JP2019532672A
(ja)
|
2016-09-28 |
2019-11-14 |
ノバルティス アーゲー |
多孔質膜系巨大分子送達システム
|
|
CA3039673A1
(en)
|
2016-10-20 |
2018-04-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of fabry disease
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
CA3041668A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
KR102709603B1
(ko)
|
2017-02-28 |
2024-09-27 |
보르 바이오파마 인크. |
계통 특이적 단백질의 억제를 위한 조성물 및 방법
|
|
JP2020513832A
(ja)
|
2017-03-22 |
2020-05-21 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
EP3612023A4
(en)
|
2017-04-20 |
2021-05-12 |
Egenesis, Inc. |
Methods for generating genetically modified animals
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615510B1
(en)
|
2017-04-28 |
2024-03-27 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US11655275B2
(en)
|
2017-05-03 |
2023-05-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
EP3645038A1
(en)
|
2017-06-30 |
2020-05-06 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
BR112020002438A2
(pt)
|
2017-08-08 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
direcionamento celular mediado por receptores de antígenos quiméricos
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
AU2018338418B2
(en)
|
2017-09-19 |
2025-06-05 |
Admare Vintageco1 Investments Ltd |
Anti-HLA-A2 antibodies and methods of using the same
|
|
BR112020005519A2
(pt)
|
2017-09-20 |
2020-10-27 |
The University Of British Columbia |
novos anticorpos anti-hla-a2 e usos dos mesmos
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
IL274323B2
(en)
|
2017-11-09 |
2024-10-01 |
Sangamo Therapeutics Inc |
Genetic modification of cytokine inducible sh2-containing protein (cish) gene
|
|
CA3082818A1
(en)
|
2017-11-15 |
2019-05-23 |
Adicet Bio Inc. |
Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof
|
|
EP3714042A4
(en)
|
2017-11-22 |
2021-08-04 |
La Jolla Institute for Allergy and Immunology |
USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
|
|
KR20220066413A
(ko)
|
2017-12-14 |
2022-05-24 |
프로디자인 소닉스, 인크. |
음향 트랜스듀서 구동기 및 제어기
|
|
US20190201548A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for engineering erythroid cells
|
|
AU2019216269B2
(en)
|
2018-01-30 |
2025-05-01 |
Cellectis |
Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
|
|
CN111954540A
(zh)
|
2018-02-08 |
2020-11-17 |
桑格摩生物治疗股份有限公司 |
工程化靶标特异性核酸酶
|
|
MX2020010459A
(es)
|
2018-04-05 |
2021-01-20 |
Juno Therapeutics Inc |
Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
|
|
KR20210020873A
(ko)
|
2018-04-05 |
2021-02-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
|
|
AU2019252527B2
(en)
|
2018-04-12 |
2024-02-22 |
Precision Biosciences, Inc. |
Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
|
|
EP3774907A1
(en)
|
2018-04-13 |
2021-02-17 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
EP3781587A4
(en)
|
2018-04-18 |
2022-03-30 |
Sangamo Therapeutics, Inc. |
ZINC FINGER PROTEIN COMPOSITIONS FOR THE MODULATION OF HUNTINGTINE (HTT)
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
|
KR20210046006A
(ko)
|
2018-08-10 |
2021-04-27 |
상가모 테라퓨틱스 프랑스 |
Tnfr2 도메인을 포함하는 신규한 car 작제물
|
|
WO2020041249A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
|
WO2020047164A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma, Inc |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
EP3853244A4
(en)
|
2018-09-18 |
2022-09-14 |
Sangamo Therapeutics, Inc. |
PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
|
|
WO2020061426A2
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
US20200102370A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
DK3908568T3
(da)
|
2019-01-11 |
2024-08-26 |
Acuitas Therapeutics Inc |
Lipider til lipidnanopartikellevering af aktivstoffer
|
|
WO2020205838A1
(en)
|
2019-04-02 |
2020-10-08 |
Sangamo Therapeutics, Inc. |
Methods for the treatment of beta-thalassemia
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
|
WO2020237045A1
(en)
|
2019-05-21 |
2020-11-26 |
Sangamo Therapeutics, Inc. |
Controlled transgene expression in regulatory t cells
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
AU2020393334A1
(en)
*
|
2019-11-25 |
2022-06-16 |
Kyoto University |
T-cell master cell bank
|
|
EP4110817A1
(en)
|
2020-02-26 |
2023-01-04 |
Sorrento Therapeutics, Inc. |
Activatable antigen binding proteins with universal masking moieties
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
MX2022011080A
(es)
|
2020-03-10 |
2023-01-04 |
Massachusetts Inst Technology |
Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas.
|
|
US20230147657A1
(en)
|
2020-03-20 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human cd45rc and uses thereof
|
|
EP4127143A1
(en)
*
|
2020-04-03 |
2023-02-08 |
Progenitor Life Sciences |
Targeting tapasin and tap complex to improve cellular immune-compatibility
|
|
US20230167191A1
(en)
|
2020-04-24 |
2023-06-01 |
Sorrento Therapeutics, Inc. |
Memory Dimeric Antigen Receptors (mDARs)
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20230181641A1
(en)
|
2020-05-13 |
2023-06-15 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
WO2021263008A1
(en)
|
2020-06-26 |
2021-12-30 |
The Regents Of The University Of California |
Selective addition of reagents to droplets
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
CA3213080A1
(en)
|
2021-03-23 |
2022-09-29 |
Krit RITTHIPICHAI |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2022243565A1
(en)
|
2021-05-21 |
2022-11-24 |
Cellectis S.A. |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
|
KR20240011184A
(ko)
*
|
2021-05-24 |
2024-01-25 |
상가모 테라퓨틱스, 인코포레이티드 |
Ciita 표적화 아연 핑거 뉴클레아제
|
|
WO2023035011A1
(en)
|
2021-09-03 |
2023-03-09 |
North Carolina State University |
Compositions and methods for conferring resistance to geminivirus
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4436982A1
(en)
|
2021-11-24 |
2024-10-02 |
Novartis AG |
Modulators of adeno-associated virus transduction and uses thereof
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
EP4544058A1
(en)
*
|
2022-06-23 |
2025-04-30 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of ciita expression
|
|
EP4547826A1
(en)
|
2022-06-30 |
2025-05-07 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
|
WO2024086591A2
(en)
*
|
2022-10-17 |
2024-04-25 |
The Regents Of The University Of California |
Stem cell based delivery of tumor-specific retroviral vectors
|
|
JP2025536578A
(ja)
|
2022-11-03 |
2025-11-07 |
セレクティス ソシエテ アノニム |
Ｔ細胞媒介免疫療法の有効性及び安全性の増進
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
AU2024214593A1
(en)
|
2023-02-03 |
2025-08-07 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2025101877A1
(en)
*
|
2023-11-08 |
2025-05-15 |
The Children's Hospital Of Philadelphia |
Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|